Literature DB >> 23079713

Genetic polymorphism of interleukin 1β -511C/T and susceptibility to sporadic Alzheimer's disease: a meta-analysis.

Hai Yuan1, Qing Xia, Pingping Ge, Shaowei Wu.   

Abstract

A large number of epidemiological studies have been performed to investigate the association between Alzheimer's disease (AD) risk and interleukin-1β -511C/T genetic polymorphism, however, inconsistent results have been reported. The effect of the IL-1β -511C/T polymorphism on AD susceptibility was evaluated by a meta-analysis. Series of databases were researched. 14 studies involving 2640 AD case and 3493 control subjects were identified. The pooled results showed there were no statistical associations of interleukin-1β -511C/T genetic polymorphism with susceptibility to AD for five analysis models in all subjects. However, obvious heterogeneity among studies was detected. When stratifying for age at onset, ethnicity and geographic distribution of population to explore the original source of heterogeneity, the meta-analysis results based on geographic distribution of population showed the significant difference (CC vs CT, OR 1.26, 95 % CI: 1.03, 1.54, z = 2.25, P = 0.025; CC vs CT+TT, OR 1.24, 95 % CI: 1.03, 1.50, z = 2.24, P = 0.025) only in non-Europe. These findings indicate that the IL-1β -511C/T polymorphism might be associated with AD risk, and individuals with IL-1β -511C/C genotype might be at higher risk of AD in non-Europe. Further larger sample research would be warranted to confirm these conclusions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079713     DOI: 10.1007/s11033-012-2237-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  36 in total

1.  Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients.

Authors:  K M Mattila; J O Rinne; T Lehtimäki; M Röyttä; J P Ahonen; M Hurme
Journal:  J Med Genet       Date:  2002-06       Impact factor: 6.318

2.  Lack of association of interleukin-1beta polymorphism with Alzheimer's disease in the Jewish population.

Authors:  Hanna Rosenmann; Zeev Meiner; Rivka Dresner-Pollak; Esther Kahana; Zoja Aladjem; Tal Grenader; Eli Wertman; Oded Abramsky
Journal:  Neurosci Lett       Date:  2004-06-10       Impact factor: 3.046

Review 3.  Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression.

Authors:  W S Griffin; J G Sheng; M C Royston; S M Gentleman; J E McKenzie; D I Graham; G W Roberts; R E Mrak
Journal:  Brain Pathol       Date:  1998-01       Impact factor: 6.508

4.  Genetic association studies of interleukin-1 (IL-1A and IL-1B) and interleukin-1 receptor antagonist genes and the risk of Alzheimer's disease.

Authors:  R L Minster; S T DeKosky; M Ganguli; S Belle; M I Kamboh
Journal:  Ann Neurol       Date:  2000-11       Impact factor: 10.422

5.  Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease.

Authors:  Michelle C McCulley; Ian N M Day; Clive Holmes
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2004-01-01       Impact factor: 3.568

6.  Interleukin-1 gene cluster polymorphisms and risk of Alzheimer's disease in Chinese Han population.

Authors:  X-Q Li; J-W Zhang; Z-X Zhang; D Chen; Q-M Qu
Journal:  J Neural Transm (Vienna)       Date:  2004-05-12       Impact factor: 3.575

7.  Assessment of Alzheimer's disease case-control associations using family-based methods.

Authors:  Brit-Maren M Schjeide; Matthew B McQueen; Kristina Mullin; Jason DiVito; Meghan F Hogan; Michele Parkinson; Basavaraj Hooli; Christoph Lange; Deborah Blacker; Rudolph E Tanzi; Lars Bertram
Journal:  Neurogenetics       Date:  2008-10-02       Impact factor: 2.660

8.  Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease.

Authors:  F L Sciacca; C Ferri; F Licastro; F Veglia; I Biunno; A Gavazzi; E Calabrese; F Martinelli Boneschi; S Sorbi; C Mariani; M Franceschi; L M E Grimaldi
Journal:  Neurobiol Aging       Date:  2003-11       Impact factor: 4.673

9.  Association of an interleukin-1beta gene polymorphism at position -511 with Alzheimer's disease.

Authors:  Christian Ehl; Heike Kölsch; Ursula Ptok; Frank Jessen; Sandra Schmitz; Christine Frahnert; Ralf Schlösser; Marie Luise Rao; Wolfgang Maier; Reinhard Heun
Journal:  Int J Mol Med       Date:  2003-02       Impact factor: 4.101

10.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  10 in total

1.  Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.

Authors:  Nicole Maphis; Guixiang Xu; Olga N Kokiko-Cochran; Shanya Jiang; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb; Kiran Bhaskar
Journal:  Brain       Date:  2015-03-31       Impact factor: 13.501

Review 2.  Periodontitis: a potential risk factor for Alzheimer's disease.

Authors:  T L Cerajewska; M Davies; N X West
Journal:  Br Dent J       Date:  2015-01       Impact factor: 1.626

Review 3.  Inflammatory Cytokines and Alzheimer's Disease: A Review from the Perspective of Genetic Polymorphisms.

Authors:  Fan Su; Feng Bai; Zhijun Zhang
Journal:  Neurosci Bull       Date:  2016-08-27       Impact factor: 5.203

4.  Association Between Interleukin-1A, Interleukin-1B, and Bridging integrator 1 Polymorphisms and Alzheimer's Disease: a standard and Cumulative Meta-analysis.

Authors:  Xiaoliu Dong; Li Zhang; Qingling Meng; Qiuyan Gao
Journal:  Mol Neurobiol       Date:  2016-01-15       Impact factor: 5.590

5.  Genetic polymorphisms of interleukin genes and the risk of Alzheimer's disease: An update meta-analysis.

Authors:  Myung-Jin Mun; Jin-Ho Kim; Ji-Young Choi; Won-Cheoul Jang
Journal:  Meta Gene       Date:  2016-01-11

6.  Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimer's disease mouse model 5xFAD.

Authors:  Antonio Boza-Serrano; Yiyi Yang; Agnes Paulus; Tomas Deierborg
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

7.  Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein.

Authors:  Anna Zettergren; Kina Höglund; Silke Kern; Valgeir Thorvaldsson; Msc Johan Skoog; Oskar Hansson; Niels Andreasen; Nenad Bogdanovic; Kaj Blennow; Ingmar Skoog; Henrik Zetterberg
Journal:  Sci Rep       Date:  2019-02-21       Impact factor: 4.379

8.  The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer's disease.

Authors:  Niklas Lonnemann; Shirin Hosseini; Carlo Marchetti; Damaris B Skouras; Davide Stefanoni; Angelo D'Alessandro; Charles A Dinarello; Martin Korte
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-30       Impact factor: 11.205

9.  Can oral infection be a risk factor for Alzheimer's disease?

Authors:  Ingar Olsen; Sim K Singhrao
Journal:  J Oral Microbiol       Date:  2015-09-17       Impact factor: 5.474

Review 10.  Targeting Neuroinflammation to Treat Alzheimer's Disease.

Authors:  A Ardura-Fabregat; E W G M Boddeke; A Boza-Serrano; S Brioschi; S Castro-Gomez; K Ceyzériat; C Dansokho; T Dierkes; G Gelders; Michael T Heneka; L Hoeijmakers; A Hoffmann; L Iaccarino; S Jahnert; K Kuhbandner; G Landreth; N Lonnemann; P A Löschmann; R M McManus; A Paulus; K Reemst; J M Sanchez-Caro; A Tiberi; A Van der Perren; A Vautheny; C Venegas; A Webers; P Weydt; T S Wijasa; X Xiang; Y Yang
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.